UY36774A - Anticuerpos de enlace-tau - Google Patents
Anticuerpos de enlace-tauInfo
- Publication number
- UY36774A UY36774A UY0001036774A UY36774A UY36774A UY 36774 A UY36774 A UY 36774A UY 0001036774 A UY0001036774 A UY 0001036774A UY 36774 A UY36774 A UY 36774A UY 36774 A UY36774 A UY 36774A
- Authority
- UY
- Uruguay
- Prior art keywords
- link
- tau antibodies
- tau
- antibodies
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
El presente invento se re refiere a anticuerpos de enlace Tau y a fragmentos de enlace de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15175519 | 2015-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36774A true UY36774A (es) | 2017-01-31 |
Family
ID=53524638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036774A UY36774A (es) | 2015-07-06 | 2016-07-06 | Anticuerpos de enlace-tau |
Country Status (23)
Country | Link |
---|---|
US (4) | US10344081B2 (es) |
EP (1) | EP3319984A1 (es) |
JP (1) | JP6937289B2 (es) |
KR (1) | KR20180027566A (es) |
CN (1) | CN107849105B (es) |
AR (1) | AR105266A1 (es) |
AU (1) | AU2016289753C1 (es) |
BR (1) | BR112017028101A2 (es) |
CA (1) | CA2991264C (es) |
CL (1) | CL2018000042A1 (es) |
CO (1) | CO2017012974A2 (es) |
EA (1) | EA036821B1 (es) |
EC (1) | ECSP18000844A (es) |
IL (1) | IL256687B (es) |
MA (2) | MA42380A (es) |
MX (1) | MX2017015908A (es) |
PE (1) | PE20180499A1 (es) |
PH (1) | PH12017502180A1 (es) |
TN (1) | TN2017000543A1 (es) |
TW (1) | TWI748954B (es) |
UY (1) | UY36774A (es) |
WO (1) | WO2017005732A1 (es) |
ZA (1) | ZA201708128B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
CA2986942A1 (en) | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
TN2017000539A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
US10889638B2 (en) | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
KR102645073B1 (ko) | 2016-12-07 | 2024-03-11 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
CA3044679A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
EP3579866A4 (en) * | 2017-02-08 | 2020-12-09 | Dragonfly Therapeutics, Inc. | HEAVY CHAIN VARIABLE ANTIBODY DOMAINS WITH NKG2D RECEPTOR AIMING |
EP3579848A4 (en) | 2017-02-08 | 2021-03-03 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR ACTIVATING NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES FOR TREATING CANCER |
MX2019009817A (es) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anticuerpos anti-tau y metodos de uso de los mismos. |
AU2018220736A1 (en) | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
MA50397A (fr) | 2017-10-16 | 2020-08-26 | Eisai R&D Man Co Ltd | Anticorps anti-tau et leurs utilisations |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
WO2020120644A1 (en) * | 2018-12-13 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | ANTIBODIES RECOGNIZING TAU PROTEIN |
BR112022020410A2 (pt) * | 2020-04-08 | 2023-01-03 | Janssen Biotech Inc | Anticorpos anti-phf-tau e usos dos mesmos |
WO2021262791A1 (en) | 2020-06-25 | 2021-12-30 | Merck Sharp & Dohme Corp. | High affinity antibodies targeting tau phosphorylated at serine 413 |
US20240101654A1 (en) * | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
DE69220503T2 (de) | 1991-10-25 | 1998-02-05 | Innogenetics Nv | Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau. |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
ATE335007T1 (de) | 1993-12-21 | 2006-08-15 | Innogenetics Nv | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
EP0772634B1 (en) | 1994-07-29 | 2003-03-12 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
EP2520588A1 (en) | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2361638B1 (en) | 2005-12-12 | 2014-01-15 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
US7803371B2 (en) * | 2008-03-26 | 2010-09-28 | Epitomics, Inc. | Anti-VEGF antibody |
CN101307108B (zh) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
WO2010144711A2 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
ES2714692T3 (es) | 2011-01-31 | 2019-05-29 | Tau Bio Logic Corp | Tratamiento de tauopatías |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
UA115657C2 (uk) | 2011-09-19 | 2017-12-11 | Аксон Ньюросайєнс Сє | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла |
EA033766B1 (ru) | 2011-11-11 | 2019-11-22 | Ucb Biopharma Sprl | Альбуминсвязывающие антитела и их связывающие фрагменты |
DK2794654T3 (da) | 2011-12-20 | 2019-08-05 | Janssen Biotech Inc | Anti-phf-tau-antistoffer og deres anvendelser |
JP6293731B2 (ja) | 2012-04-05 | 2018-03-14 | エーシー イミューン エス.エー. | ヒト化タウ抗体 |
KR20150036346A (ko) | 2012-07-03 | 2015-04-07 | 워싱턴 유니버시티 | Tau에 대한 항체 |
WO2014016737A1 (en) | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
ME03667B (me) | 2012-08-16 | 2020-10-20 | Ipierian Inc | Metodi lečenja tauopatije |
BR112015014751A8 (pt) | 2012-12-21 | 2018-01-16 | Biogen Int Neuroscience Gmbh | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
BR112015023262B8 (pt) | 2013-03-15 | 2024-02-06 | Ac Immune Sa | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo |
PL3083680T3 (pl) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
CA2986942A1 (en) | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
TN2017000539A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
-
2016
- 2016-07-05 TN TNP/2017/000543A patent/TN2017000543A1/en unknown
- 2016-07-05 CA CA2991264A patent/CA2991264C/en active Active
- 2016-07-05 CN CN201680039813.9A patent/CN107849105B/zh active Active
- 2016-07-05 KR KR1020187003686A patent/KR20180027566A/ko not_active Application Discontinuation
- 2016-07-05 BR BR112017028101A patent/BR112017028101A2/pt active Search and Examination
- 2016-07-05 US US15/742,070 patent/US10344081B2/en active Active
- 2016-07-05 MA MA042380A patent/MA42380A/fr unknown
- 2016-07-05 PE PE2017002758A patent/PE20180499A1/es unknown
- 2016-07-05 JP JP2018500422A patent/JP6937289B2/ja active Active
- 2016-07-05 MA MA41669A patent/MA41669A1/fr unknown
- 2016-07-05 MX MX2017015908A patent/MX2017015908A/es unknown
- 2016-07-05 WO PCT/EP2016/065809 patent/WO2017005732A1/en active Application Filing
- 2016-07-05 EA EA201890169A patent/EA036821B1/ru not_active IP Right Cessation
- 2016-07-05 AU AU2016289753A patent/AU2016289753C1/en active Active
- 2016-07-05 EP EP16736072.6A patent/EP3319984A1/en active Pending
- 2016-07-06 TW TW105121454A patent/TWI748954B/zh active
- 2016-07-06 AR ARP160102044A patent/AR105266A1/es unknown
- 2016-07-06 UY UY0001036774A patent/UY36774A/es not_active Application Discontinuation
-
2017
- 2017-11-29 ZA ZA2017/08128A patent/ZA201708128B/en unknown
- 2017-11-29 PH PH12017502180A patent/PH12017502180A1/en unknown
- 2017-12-18 CO CONC2017/0012974A patent/CO2017012974A2/es unknown
-
2018
- 2018-01-01 IL IL256687A patent/IL256687B/en unknown
- 2018-01-05 CL CL2018000042A patent/CL2018000042A1/es unknown
- 2018-01-05 EC ECIEPI2018844A patent/ECSP18000844A/es unknown
-
2019
- 2019-07-01 US US16/458,217 patent/US10906966B2/en active Active
-
2020
- 2020-12-29 US US17/136,440 patent/US11746145B2/en active Active
-
2023
- 2023-06-30 US US18/344,930 patent/US20230331833A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36774A (es) | Anticuerpos de enlace-tau | |
UY36773A (es) | Anticuerpos de enlace-tau | |
DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
DK3697376T3 (da) | Sammensætning | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
MA43259A (fr) | Liants ctla4 | |
DK3242892T3 (da) | Modificerede april-bindende antistoffer | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
DK3452507T3 (da) | Tau-immunoterapi | |
DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DK3478999T3 (da) | Offerafskærmning | |
KR20180085013A (ko) | 접착제 조성물 | |
DK3368627T3 (da) | Klæbemiddelsammensætning | |
UA38192S (uk) | Закріплюваний на голові дисплей | |
ES1209313Y (es) | Composicion liofilizada | |
UA37345S (uk) | Вивіска | |
UA37346S (uk) | Вивіска | |
UA37347S (uk) | Вивіска | |
UA36013S (uk) | Вивіска | |
UA35896S (uk) | Вивіска | |
UA35895S (uk) | Вивіска | |
UA36874S (uk) | Календар |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20221125 |